Search Results
The product title you are looking for is no longer available. Other similar products that may interest you are listed below:
| Title | Publication Date | Price | Relevance |
|---|---|---|---|
| Hormone Refractory Prostate Cancer - Pipeline Review H2 2011 |
Nov 2011 | £315 | 100% |
| Prostate Cancer - Pipeline Review H2 2011 |
Sep 2011 | £315 | 98% |
| Biomarkers (2 parts) Technologies, Markets and Companies |
Jan 2012 | £3,240 | 98% |
| A Decision Support Tool for Optimizing the Prostate Cancer Pipeline From Research and Development to Market |
May 2010 | £1,620 | 97% |
| Oncology Therapeutics Market to 2017 High Unmet Need in the Management and Treatment of Metastatic Cancers to Drive Drug Development |
Dec 2011 | £2,215 | 96% |
| Drug Discovery and Preclinical Molecules by Therapy Area Innovation Focuses on Stem Cell Therapies and Gene Therapies |
Feb 2011 | £2,215 | 94% |
| Chemotherapy Market Insights, 2006-2016 A Critical Analysis of Cancer Research, Treatments, Pipelines, and Commercial Opportunities |
Apr 2006 | £1,900 | 94% |
| Prostate Cancer Therapeutics A Global Market Perspective |
Nov 2009 | £1,895 | 93% |
| Prostate Cancer Therapeutics | Apr 2009 | £2,500 | 93% |
| Cancer Biomarkers Adoption Is Driving Growth |
Jul 2008 | £2,370 | 91% |
| Strategic Outlook on Protein Kinase Inhibitors in Oncology | Feb 2006 | £1,620 | 91% |
| Targeted Therapies in Oncology A World Review |
Dec 2006 | £4,110 | 90% |
| Global Biochip Markets Microarrays and Lab-on-a-Chip |
Aug 2011 | £3,065 | 90% |
| GPCRs in Drug Discovery Efforts to De-Orphanize Novel Gpcr Targets Are Increasing |
Nov 2011 | £2,215 | 90% |
| Innovations in Cancer Novel Therapeutics, New Diagnostics and Future R&D Strategies |
Feb 2007 | £1,820 | 88% |
| Top 10 Healthcare Trends in 2011 | Mar 2011 | £2,215 | 88% |
| Biomarker Technology Platforms for Cancer Diagnoses and Therapies | Sep 2011 | £2,150 | 88% |
| Competitive Outlook on Non-Antibody Based Cancer Vaccines | Aug 2006 | £1,620 | 87% |
| Bone Cancer - Pipeline Review H2 2011 |
Nov 2011 | £315 | 87% |
| Preclinical Cancer Therapeutics 2007 Decoding Next Generation Drug Targets for Market Success |
Dec 2006 | £1,600 | 86% |
| Advancing Molecular Diagnostics to Personalize Cancer Therapy | Jun 2011 | £2,425 | 86% |
| The Future of Oncology Therapeutics Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis |
Dec 2009 | £2,215 | 86% |
| Biomarkers: A Market Briefing A Market Briefing |
Jan 2007 | £1,260 | 86% |
| Dendreon Corporation – Product Pipeline Review H2 2011 |
Nov 2011 | £315 | 85% |
| Drug Delivery in Cancer (2 pt) Technologies, Markets and Companies |
Jan 2012 | £2,590 | 84% |
| Therapeutic Monoclonal Antibodies Markets | Jun 2009 | £1,265 | 84% |
| RNAi Technologies, Markets and Companies |
Jan 2012 | £2,590 | 83% |
| Molecular Diagnostics in Cancer Testing | Jul 2011 | £2,150 | 83% |
| Targeting Cancer Stem Cells Therapeutic Strategies and Pipeline Developments (2010) |
Jan 2010 | £1,599 | 83% |
| Targeting Cancer Stem Cells Therapeutic Strategies, Pipeline, Biomarkers and Opportunities (2010) |
Jan 2010 | £1,599 | 83% |
